Skip to main content
Premium Trial:

Request an Annual Quote

Codon Devices, Blue Heron Settle Litigation

NEW YORK (GenomeWeb News) – Codon Devices and Blue Heron Technology announced today that they have settled a patent infringement suit filed last year by Codon against Blue Heron.
Codon sued the Bothell, Wash.-based gene synthesis firm in March 2007 for allegedly infringing five patents exclusively licensed to Codon by Duke University and the Massachusetts Institute of Technology. The suit, filed in a US District Court in Delaware, claimed that Blue Heron infringed Duke patents used to map gene mutations, manipulate genes, and fractionate DNA molecules, and an MIT patent used to screen for genetic variation.
As part of the settlement, Codon granted Blue Heron a perpetual, fully paid sublicense to continue to use error correction technology employed in its gene synthesis activities. Cambridge, Mass.-based Codon also said that it would ask the court to dismiss its suit against Blue Heron.
Financial terms of the settlement were not disclosed.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.